ALK and colorectal carcinoma: The availability of NGS facilitates a therapeutic genomic paradigm to classify CRC based on actionable genomic biomarkers such as RET, ALK, NTRK, ROS and ERBB2, which may facilitate the clinical trial development of a Colorectal Cancer Genomic Protocol (Figure 4B).